Cullinan Therapeutics has received FDA and Australian regulatory clearance to begin a global Phase 1b/2a clinical trial of velinotamig, a BCMAxCD3 T cell engager, targeting relapsing and refractory immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). These serious autoimmune blood disorders cause destruction of platelets and red blood cells, leading to severe symptoms and reduced quality of life. The trial will assess safety, tolerability, and preliminary efficacy of a short subcutaneous dosing regimen designed to deplete antibody-producing plasma cells. This study expands Cullinan's immunology portfolio and could offer a new treatment option for patients with persistent or relapsing disease who have limited current therapies.
Cullinan Therapeutics' advancement of velinotamig into global clinical development follows recent regulatory clearances. For readers following the health sector, here is Pluang's market snapshot as of Oct 27, 2026 17:02 WIB: out of 150 priced US health stocks, 60 rose and 78 fell today. Notable movers include Centene Corp (CNC) at USD 65.00 with a 1-day change of -4.51% and a typical hold time on Pluang of 43 days, BioNano Genomics Inc (BNGO) at USD 1.12 with a 1-day change of -3.45% and 100% sell order activity, and Cronos Group Inc (CRON) at USD 3.41 with a 1-day change of +3.02% and a typical hold time of 23 days.
Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...
eSoftware Associates advises defense contractors to carefully map controlled unclassified information (CUI) access permissions before licensing Microsoft 365 Copilot in the GCC High cloud environment. Moving to GCC High does not automatically grant c...
Nautilus Biotechnology announced its Q3 2026 financial results, reporting $0.2 million in revenue mainly from grants and early access services, and a net loss of $15.6 million. The company highlighted progress in its proteome analysis platform, inclu...
Eviden, part of Atos Group, has introduced ASTRA-LAS, a tactical decision-support solution designed to aid naval officers in complex maritime environments. The system uses operational data and AI to enhance situational awareness, reduce cognitive loa...
Eviden, part of Atos Group, has introduced ASTRA-LAS, a new AI-powered tactical assistant designed to support naval operations by providing enhanced visualizations, automated analyses, and mission-specific recommendations. This system helps naval off...
